Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Lorazepam may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Lorazepam is a member of a group of medicines called benzodiazepines. It can help to relieve severe anxiety. Lorazepam is prescribed as short-term therapy for anxiety (2-4 weeks), or sleeping difficulties due to anxiety that significantly affects normal daily life. It may also be used as a sedative before surgery or operative dental treatment. This medicine has been prescribed to you and should not be given to anyone else Lorazepam is not to be used for longer than 4 weeks or to treat mild or moderate anxiety in adults. Benzodiazepines can cause dependence, tolerance and addiction, and you may get withdrawal symptoms if you stop taking it or reduce the dose suddenly. Your prescriber should have explained how long you will be taking it for and, when it is appropriate to stop, how to do this safely. When your treatment is stopped, it is usually done gradually over a period which is specific to you and may occur over a period of weeks to months. You must talk to a doctor if you do not feel better or if you feel worse. 2.
e Lorazepam
Do not take Lorazepam: if you have severe breathing or chest problems if you are allergic to lorazepam, other benzodiazepines or any of the other ingredients of this medicine (listed in section 6) VAR/IB-012
1.3.1 Package leaflet
if you have myasthenia gravis (very weak or tired muscles) if you have serious liver problems if you suffer from sleep apnoea (breathing problems when you are asleep)
If you have been only prescribed Lorazepam for anxiety and no other medications, please consult with your doctor whether other medications should also be prescribed. Some elderly patients may feel dizzy after taking lorazepam and may be in danger of falling. Warnings and precautions Talk to your doctor or pharmacist before taking Lorazepam: if you are pregnant or trying to become pregnant are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs, or if you have ever had a history of struggling to control your alcohol or drug intake. have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating, when you have stopped taking alcohol or drugs. feel you need to take more of lorazepam to get the same level of symptom control, this may mean you are developing tolerance to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative medication. if you have a personality disorder. If so, you have a greater chance of becoming dependent on lorazepam if you have any kidney or liver problems if you are elderly or debilitated (weak) if you have suffered from depression before, since it could re-occur during treatment with lorazepam if you are suffering from depression, since lorazepam may increase any suicidal feelings which you may have if you have a history of psychotic illness if you have a history of convulsions/seizures if you suffer from breathing problems if you are suffering from an eye problem called glaucoma e.g. high pressure within the eye if you are taking any other medicines, including those which have not been prescribed by a doctor, since they may affect the way Lorazepam works. Lorazepam may also affect the way other drugs work. Lorazepam may cause muscle relaxation and caution is advised as you may be at a greater risk of falling (see section 4). Taking this medicine regularly, particularly for a long time, can lead to physical dependence and addiction. Your prescriber should have explained how long you will be taking it for and, when it is appropriate to stop, how to do this safely. When your treatment is stopped, it is usually done gradually over a period which is specific to you and may occur over a period of weeks to months. Physical dependence and addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include: Headaches, muscle pain, anxiety, tension, depression, restlessness, sweating, confusion or irritability. Do not stop taking your solution suddenly. This could lead to more serious symptoms such as loss of the sense of reality, feeling unreal or detached from life, and unable VAR/IB-012
1.3.1 Package leaflet
to feel emotion. Some patients have also experienced numbness or tingling of the arms or legs, tinnitus (ringing sounds in the ears), oversensitivity to light, sound and touch, uncontrolled or overactive movements, twitching, shaking, feeling sick, being sick, stomach upsets or stomach pain, loss of appetite, agitation, abnormally fast heartbeats, panic attacks, dizziness or feeling that you are about to fall, memory loss, hallucinations, feeling stiff and unable to move easily, feeling very warm, convulsions (sudden uncontrolled shaking or jerking of the body). Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Your prescriber will ensure that your plan for stopping treatment is tailored to you and can be adapted according to your needs and experience of any withdrawal symptoms. Benzodiazepines should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of benzodiazepines, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. Other medicines and Lorazepam Tell your doctor or pharmacist (including at hospital if you enter for treatment) if you are taking, have recently taken or might take any other medicines, including those which have not been prescribed by a doctor, since they may affect the way Lorazepam works. Lorazepam may also affect the way other medicines work. In particular, you should tell your doctor if you are taking: any other sedative (e.g. barbiturates) anti-anxiety drugs anti-depressants probenecid (a drug to treat gout) strong pain killers (e.g. opioids – keep the dosages and duration of the medicine to a minimum as recommended by your doctor). Taking Lorazepam with these pain killers may make you more sleepy and in rare cases can cause breathing difficulty and death. drugs for epilepsy (e.g. phenobarbital or sodium valproate) antihistamines anti-psychotic drugs for mood or mental disorders (e.g. chlorpromazine, loxapine or clozapine) anaesthetics drugs for cataplexy (sudden and temporary muscular weakness triggered by strong emotions such as laughter, anger and surprise) drugs for treating HIV drugs to treat delusions or hallucinations drugs to help with indigestion (e.g. omeprazole) muscle relaxants (e.g. baclofen and tizanidine) drugs for addiction treatment (e.g. methadone, lofexidine and disulfiram) drugs to treat tuberculosis (e.g. isoniazid and rifampicin) antibiotics such as erythromycin drugs to treat high blood pressure drugs to treat Parkinson's disease e.g. levodopa oestrogen-containing contraceptives drugs for asthma (theophylline, aminophylline) VAR/IB-012
1.3.1 Package leaflet
The dose of these drugs may need to be reduced before you can take lorazepam. Concomitant use of lorazepam and opioids (strong pain killers, medicines for substitution therapy and some cough medicines) increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However, if your doctor does prescribe lorazepam together with opioids the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all opioid medicines you are taking and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Lorazepam with food, drink and alcohol Grapefruit juice and drinks containing caffeine should be avoided as they can affect the way that Lorazepam works. Alcohol will increase the sedative effects of lorazepam and should therefore be avoided. Things to note before taking lorazepam Tell your doctor or pharmacist that you are taking lorazepam before taking any other medicine or if you enter hospital for treatment. Some elderly patients may feel dizzy after taking lorazepam and may be in danger of falling. Increases in the dosage of lorazepam should be made gradually to help avoid adverse effects. The evening dose should be increased before the daytime doses. If you are given lorazepam for more than 4 weeks, your doctor might want to take blood samples occasionally to check your blood and liver, since drugs like lorazepam have occasionally affected liver function. Tolerance and dependence Tolerance to benzodiazepines may occur. Therefore the beneficial effect of lorazepam may be less apparent after several weeks of use. Lorazepam may have abuse potential, especially in patients with a history of drug and/or alcohol abuse. Dependence is unlikely to occur but the risk increases with higher doses and longer-term use and is further increased in patients with a history of alcoholism, drug abuse or in patients with personality disorders. Therefore use in individuals with a history of alcoholism or drug abuse should be avoided. Dependence may lead to withdrawal symptoms, especially if treatment is discontinued abruptly. Therefore, the drug should always be discontinued gradually. Dependence on benzodiazepines may occur following prolonged treatment. Dependence on benzodiazepines may occur following prolonged treatment. Therefore lorazepam is usually prescribed for short courses of treatment, lasting from a few days to 4 weeks including a dose reduction at the end. This reduces the risk of becoming dependent on VAR/IB-012
1.3.1 Package leaflet
lorazepam, or suffering unpleasant effects when you stop taking it. (See section 3 'If you stop taking lorazepam', below). Increases in the dosage of lorazepam should be made gradually to help avoid adverse effects. The evening dose should be increased before the daytime doses. Pregnancy, breast-feeding and fertility If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Benzodiazepines, including lorazepam may cause damage to the foetus if taken during early pregnancy. If you take this medicine during late pregnancy or during labour, your baby, when born, may be less active than other babies, have a low body temperature, be floppy or have breathing or feeding difficulties for a while. Your baby's response to the cold might be temporarily impaired also. If this medicine is taken regularly in late pregnancy, your baby may develop withdrawal symptoms after birth. Lorazepam should not be given to breastfeeding mothers unless the expected benefit to the mother outweighs the potential risk to the infant, as the drug may pass into breast milk. Driving and using machines Lorazepam may make you feel dizzy, sleepy or forgetful during the day, or may affect your concentration. This may affect your performance at skilled tasks such as driving machinery or operating machinery by affecting your vision or muscle function. You should not take part in any other activities where this could put yourself or others at risk. You should avoid alcohol while you are taking lorazepam, since this may make you very drowsy and seriously affect your ability to drive or use machines. The medicine can affect your ability to drive as it may make you feel sleepy or dizzy. Do not drive while taking this medicine until you know how it affects you. It is an offence to drive if this medicine affects your ability to drive. However, you would not be committing an offence if: • The medicine has been prescribed to treat a medical or dental problem and • You have taken it according to the instructions given by the prescriber or in the information provided with the medicine and • It was not affecting your ability to drive safely. Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine. Lorazepam 1mg/ml Oral Solution contains: This medicine contains 20.21mg ethanol (alcohol) per ml. The amount in each ml of this medicine is equivalent to less than 1ml beer or 1ml wine. The small amount of alcohol in this medicine will not have any noticeable effects.
VAR/IB-012
1.3.1 Package leaflet
3.
Lorazepam
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Your prescriber should have discussed with you how long the course of lorazepam will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Your prescriber will ensure that your plan for stopping treatment is tailored to you and can be adapted according to your needs and experience of any withdrawal symptoms. The recommended dose Adults Anxiety: 1 – 4ml (1 – 4mg) daily in divided doses. Your doctor will tell you how often to take the medicine. Sleeping Problems: 1 – 2ml (1 – 2mg) before going to sleep. You should make sure that you will be able to sleep for 7 to 8 hours before taking the medicine. Before Surgery: 2 – 3ml (2 – 3mg) the night before your operation and 2 – 4ml (2 – 4mg) 1 or 2 hours before your operation. Elderly patients Elderly and debilitated (weak) patients may be given lower doses. They may respond to half the usual adult dose or less. However, this lower dose may be adjusted if needed. Patients with Renal or Hepatic Impairment Lower doses may be sufficient in patients with impaired renal function or mild to moderate hepatic insufficiency. Use in patients with severe hepatic insufficiency is contraindicated. Lorazepam is not recommended for use in children. Lorazepam is usually prescribed for short courses of treatment, lasting from a few days to 4 weeks including a dose reduction at the end. This reduces the risk of becoming dependent on Lorazepam, or suffering unpleasant effects when you stop taking the medicine (See 'If you stop taking Lorazepam' section). The beneficial effect of lorazepam may be less apparent after several weeks of use. If you are given lorazepam for more than 4 weeks, your doctor might want to take blood samples occasionally to check your blood and liver, since drugs like lorazepam have occasionally affected blood and liver function. Method of administration: This medicinal product contains medium chain triglycerides which reacts with polystyrene materials and makes it brittle upon contact. Do not use polystyrene dosing devices for measuring the dose. Use the measuring syringe provided in the pack to deliver the required dose orally. The required dose should be drawn from the container into the graduated syringe provided using the syringe adaptor (see detailed instructions below). The syringe should be held in the mouth of the patient, and the contents of the syringe should then be ejected into the mouth and swallowed.
VAR/IB-012
1.3.1 Package leaflet
Instructions for the use of syringe: a) Open the bottle: press the cap and turn it anticlockwise (figure 1). b) Separate the adaptor from the syringe (figure 2). Insert the adaptor into the bottle neck (figure 3). Ensure it is properly fixed. Take the syringe and put it in the adaptor opening (figure 4).
c)
Turn the bottle upside down. Fill the syringe with a small amount of solution by pulling the piston down (figure 5A), then push the piston upwards in order to remove any possible bubble (figure 5B). Pull the piston down to the graduation mark corresponding to the quantity in millilitres (ml) prescribed by your doctor (figure 5C).
d)
Turn the bottle the right way up (figure 6A). Remove the syringe from the adaptor (figure 6B).
e)
Empty the contents of the syringe into the patient's mouth by pushing the piston to the bottom of the syringe (figure 7). The contents of the syringe should be emptied into the side cheek of the patient's mouth to avoid a choking hazard. Leave the syringe adaptor in place after first use. Close the bottle with the plastic screw cap. Wash the syringe with water (figure 8).
VAR/IB-012
1.3.1 Package leaflet
If you take more Lorazepam than you should If anyone has taken an overdose of Lorazepam (that is more than the doctor has prescribed), seek medical help immediately, either by calling your doctor, or going to the nearest casualty department. Always take the labelled medicine pack with you, even if no medicine is left. If you forget to take Lorazepam If you forget to take your medicine for anxiety, you should take it as soon as you remember if it is less than 3 hours since your usual time. If more than 3 hours has passed from when you usually take your medicine, just take your next dose when it is due. Do not take a double dose to make up for a forgotten dose. If you forget to take your medicine for sleeping problems, only take it if you will be able to sleep for 7 to 8 hours afterwards. If you stop taking Lorazepam After you have finished your prescribed treatment with lorazepam, your doctor will decide if you need further treatment. The amount of Lorazepam and how often you take your medicine should always be reduced slowly before stopping it. This allows your body to get used to being without your medicine, and reduces the risk of unpleasant effects when you stop taking the medicine. Your doctor will tell you how to do this. Your original sleeplessness may also return. If you suffer from any of these symptoms, ask your doctor for advice. Patients taking anti-depressants and patients with seizure disorders may be more likely to experience convulsions. Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. This may occur over a period of weeks to months. Your prescriber will ensure that your plan for stopping treatment is tailored to you and can be adapted according to your needs and experience of any withdrawal symptoms. Withdrawal symptoms such as: headaches, muscle pain, anxiety, tension, depression, restlessness, sweating, confusion or irritability. Do not stop taking your solution suddenly. This could lead to more serious symptoms such as loss of the sense of reality, feeling unreal or detached from life, and unable to feel emotion. Some patients have also experienced numbness or tingling of the arms or legs, tinnitus (ringing sounds in the ears), oversensitivity to light, sound and touch, uncontrolled or overactive movements, twitching, shaking, feeling sick, being sick, stomach upsets or stomach pain, loss of appetite, agitation, abnormally fast heartbeats, panic attacks, dizziness or feeling that you are about to fall, memory loss, hallucinations, feeling stiff and unable to move easily, feeling very warm, convulsions (sudden uncontrolled shaking or jerking of the body). If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
VAR/IB-012
1.3.1 Package leaflet
4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you experience any of the following serious unwanted effects, you should tell your doctor immediately (these effects are more likely to occur in elderly patients): Severe allergic reactions can occur with benzodiazepine use, even after the first dose. Symptoms include swelling of the tongue or throat, shortness of breath, throat closing, nausea or vomiting. In such cases, immediate medical attention should be sought. Benzodiazepines, including lorazepam, may lead to potentially fatal breathing problems. Restlessness, agitation, irritability, aggressiveness, violent anger, sleeping difficulties, nightmares, hallucinations, personality changes, sexual arousal, abnormal behaviour or false beliefs Unexplained bleeding and/or bruising; increased risk of infections e.g. frequent sore throats, mouth ulcers, weakness and pale skin as these are symptoms of blood dyscrasia Impaired consciousness (e.g. reduced alertness, confusion, disorientation, fainting) as this may ultimately lead to coma Thoughts of harming or killing yourself, becoming dependent on Lorazepam Severe allergic reactions e.g. difficulty in breathing, swelling of the lips, mouth, tongue, throat, hands, feet and/or severe faintness or dizziness Jaundice e.g. yellowing of the skin, eyes, nose, mouth, pale coloured stools (faeces) and dark coloured urine Other side effects Very common: may affect more than 1 in 10 people Drowsiness, fatigue, sedation Common: may affect up to 1 in 10 people Dizziness, muscle weakness, Asthenia (loss of strength), Ataxia (poor muscle control), Confusion, Depression, unmasking of depression (revealing signs of depression that were previously hidden) Uncommon: may affect up to 1 in 100 people Nausea, Change in libido, Impotence, Decreased orgasm Not known: frequency cannot be estimated from the available data Increased sensitivity to light, sound and touch; Convulsions/fits, constipation, yellowing of the skin and eyes, Shaking, Problems with vision (double and blurred vision), Slurred speech, Headache, Memory loss, Heightened emotions, Coma, Impaired attention/concentration, Loss of inhibitions, Thoughts or attempts of suicide, Increase in specific liver enzymes (bilirubin, liver transaminases and alkaline phosphatase), Anxiety, excitation, hostility, aggression, sexual arousal, balance disorder, Difficulty breathing, Difficulty breathing when you are asleep, Worsening of lung disease, Allergic skin reactions (e.g. rash, swelling), Alopecia (loss of hair from the head or body), Hypersensitivity reactions, Angioedema (swelling of the face, hands and feet), SIADH – syndrome of inappropriate antidiuretic hormone hypersecretion (a condition in which the body produces too much antidiuretic hormone (ADH). Increased ADH may cause too much water to remain inside your body.), Hyponatremia (low level of sodium in the blood which can cause tiredness and confusion, muscle twitching, fits and coma), Hypothermia, Lowering of blood pressure, VAR/IB-012
1.3.1 Package leaflet
Thrombocytopenia (unexplained bruising, nosebleeds and/or bleeding gums), agranulocytosis (severe infection), pancytopenia (bleeding, bruising easily, fatigue, shortness of breath, and weakness), Vertigo, Problems sleeping, Drug abuse, dependence and addiction (see section "How do I know if I am tolerant or addicted?"), Drug withdrawal syndrome. The following side effects may be more likely to occur in elderly patients: Restlessness Agitation Irritability Aggressiveness Violent anger Nightmares Hallucinations Personality changes Abnormal behaviour False beliefs If any of the side-effects get serious, or if you notice any side-effects not listed in this leaflet, please tell your doctor or pharmacist. Drug Withdrawal When you stop taking lorazepam, you may experience drug withdrawal symptoms, which include: headaches, muscle pain, anxiety, tension, depression, restlessness, sweating, confusion or irritability. Do not stop taking your solution suddenly. This could lead to more serious symptoms such as loss of the sense of reality, feeling unreal or detached from life, and unable to feel emotion. Some patients have also experienced numbness or tingling of the arms or legs, tinnitus (ringing sounds in the ears), oversensitivity to light, sound and touch, uncontrolled or overactive movements, twitching, shaking, feeling sick, being sick, stomach upsets or stomach pain, loss of appetite, agitation, abnormally fast heartbeats, panic attacks, dizziness or feeling that you are about to fall, memory loss, hallucinations, feeling stiff and unable to move easily, feeling very warm, convulsions (sudden uncontrolled shaking or jerking of the body). How do I know if I am tolerant or addicted? If you notice any of the following signs whilst taking <product name>, it could be a sign that you have become addicted. You may feel the need to keep taking the medication for longer than your doctor recommended You feel you need to use more than the recommended dose You are using the medicine for reasons other than prescribed When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again If you notice any of these signs, it is important you talk to your prescriber. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
VAR/IB-012
1.3.1 Package leaflet
5.
6.
Lorazepam Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month. Store and transport refrigerated (2C – 8C). For 60ml pack size: Discard 30 days after first opening. For 150ml pack size: Discard 90 days after first opening. Keep the bottle in the outer carton in order to protect from light. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Lorazepam contains The active substance is lorazepam. Each ml of oral solution contains 1mg lorazepam. The other ingredients are ethanol (alcohol) and medium chain triglycerides. What Lorazepam looks like and contents of the pack Lorazepam is a clear, colourless to pale yellow colour oral solution supplied in an amber glass bottle, holding 60ml or 150ml of solution, with tamper evident child resistant plastic cap. The pack also contains a 1ml oral syringe and a bottle/syringe adaptor. Not all pack sizes may be marketed. POM Marketing Authorisation Holder and Manufacturer: SyriMed, Unit 4, Bradfield Road, Ruislip, Middlesex, HA4 0NU, UK. If this leaflet is hard to see or read, please call +44 (0) 208 515 3700 for help. This leaflet was last revised in 01/2026.
VAR/IB-012
1.3.1 Package leaflet
Lorazepam 1mg/ml Oral Solution comes as oral solution containing 1mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Lorazepam 1mg/ml Oral Solution is lorazepam.
This leaflet reproduces the patient information leaflet approved for Lorazepam 1mg/ml Oral Solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
FOR SHORT TERM (2-4 weeks only) USE
• Symptomatic relief of anxiety that is severe, disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness.
AS PREMEDICATION
• Before operative dentistry and general surgery
NOT FOR USE
• Long term (i.e. longer than 4 weeks)
• For mild/moderate anxiety
Lorazepam Oral Solution is not recommended for use in children.
Prior to starting treatment with lorazepam, a discussion should be held with patients to put in place a strategy for ending treatment with lorazepam in order to minimise the risk of dependence, addiction and drug withdrawal syndrome (see section 4.4).
Treatment should be given for the shortest possible duration.
Route of administration: oral
Treatment to be given:
• Under close medical supervision
• At the lowest effective dose
• For the shortest possible duration (not exceeding 4 weeks)
Doses should be individualised.
Extension of use should not take place without further clinical evaluation.
Chronic use not recommended (little is known of the long term safety and efficacy; potential for dependence) (see section 4.4).
Increases in the dosage of lorazepam should be made gradually to help avoid adverse effects. The evening dose should be increased before the daytime doses.
When treatment is started the patient should be informed that
• Treatment will be of limited duration
• The dosage will be progressively decreased
• There is a possibility of withdrawal and rebound phenomena which is greater after abrupt discontinuation; therefore, the drug should be discontinued gradually for all patients (see section 4.4). Generally, the duration of treatment varies from a few days to 4 weeks including the tapering off process.
Dosage:
Adults:
• Anxiety: 1 - 4ml (1 - 4mg) daily in divided doses.
• Insomnia: 1 - 2ml (1 - 2mg) before retiring
• Premedication before operative dentistry or general surgery: 2 - 3ml (2 - 3mg) the night before operation 2 - 4ml (2 - 4mg) one to two hours before the procedure
Elderly and debilitated patients:
For elderly and debilitated patients reduce the initial dose by approximately 50% and adjust the dosage as needed and tolerated (see section 4.4 Special warnings and precautions for use).
Patients with Renal or Hepatic impairment:
Lower doses may be sufficient in patients with impaired renal function or mild to moderate hepatic insufficiency (see section 4.4). Use in patients with severe hepatic insufficiency is contraindicated (see section 4.3)
Method of administration
For oral use only.
• Hypersensitivity to lorazepam, benzodiazepines or to any of the other excipients listed in section 6.1
• Severe respiratory insufficiency: respiratory depression; sleep apnoea (risk of further respiratory depression)
• Severe hepatic insufficiency (may precipitate encephalopathy)
• Myasthenia gravis;
Benzodiazepines should not be used alone in depression or anxiety with depression (may precipitate suicide)
Use of benzodiazepines, including lorazepam, may lead to potentially fatal respiratory depression.
Severe anaphylactic/anaphylactoid reactions have been reported with the use of benzodiazepines. Cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of benzodiazepines. Some patients taking benzodiazepines have had additional symptoms such as dyspnoea, throat closing, or nausea and vomiting. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with a benzodiazepine should not be rechallenged with the drug.
Lorazepam should be used with caution in patients with compromised respiratory function (e.g., COPD, sleep apnoea syndrome).
Patients should be advised that since their tolerance for alcohol and other CNS depressants will be diminished in the presence of lorazepam, these substances should either be avoided or taken in reduced dosage.
Anxiety or insomnia may be a symptom of several other disorders. The possibility should be considered that the complaint may be related to an underlying physical or psychiatric disorder for which there is more specific treatment.
Abuse of benzodiazepines has been reported, especially in patients with a history of drug and/or alcohol abuse.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Limit dosages and durations to the minimum required.
Drug dependence, tolerance and potential for abuse
Drug addiction comprises behavioural, cognitive and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use and possible tolerance or physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, which manifests as withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Addiction and dependence are related but distinct presentations and in discussing these themes, terminology that apportion blame to the individual should be avoided.
For all patients, prolonged use of this product may lead to drug dependence and addiction but can occur with short-term use at recommended therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).
Additional support and monitoring may be necessary when prescribing for patients at risk of drug misuse.
A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of symptom control as initially experienced. Patients may also supplement their treatment with additional medications to achieve the same effect. These could be signs that the patient is developing tolerance. The risks of developing tolerance should be explained to the patient.
Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction.
The clinical need for treatment with <active> should be reviewed regularly, with frequent assessments of patients being undertaken during the course of their treatment.
Drug withdrawal syndrome
Prior to starting treatment with lorazepam, a discussion should be held with patients to explain the risk of dependence, addiction, and drug withdrawal syndrome. A withdrawal strategy for ending treatment with lorazepam should also be put in place with the patient before starting treatment (there may be exceptions to this in specific clinical situations such as symptom management in end of life palliative care)
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take in excess of weeks or months. Patients should be informed of this when the medication is first prescribed.
The reduction schedule for a patient should be tailored to the individual and should be modified to allow intolerable withdrawal symptoms to improve before making the next reduction. If using a published withdrawal schedule, apply it flexibly to accommodate the person's preferences, changes to their circumstances and the response to dose reductions.
Suggest a slow stepwise rate of reduction proportionate to the existing dose, so that decrements become smaller as the dose is lowered, unless clinical risk is such that rapid withdrawal is needed.
If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Withdrawal Reactions
Dependence may lead to withdrawal symptoms, especially if treatment is discontinued abruptly. Therefore, the drug should always be discontinued gradually.
Withdrawal symptoms (e.g. rebound insomnia) can appear following cessation of recommended doses after as little as one week of therapy.
Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may precipitate withdrawal reactions, which can be life-threatening. These can range from mild dysphoria and insomnia to a major syndrome which may include abdominal and muscle cramps, vomiting, sweating, tremor, and convulsions. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. Convulsions/seizures may occur more often in patients with preexisting seizure disorders or in patients who take other drugs that lower the convulsive threshold, such as antidepressants.
The following symptoms have also been described: headache, anxiety, tension, restlessness, confusion and irritability, dizziness, dysphoria, derealisation, depersonalisation, hyperacusis, tinnitus, numbness and tingling of the extremities, hypersensitivity to light, noise, and physical contact/perceptual changes, involuntary movements, nausea, diarrhoea, loss of appetite, panic attacks, myalgia/muscle pain, agitation, palpitations, tachycardia, vertigo, hyperreflexia, short-term memory loss and hyperthermia.
Occurrence of "rebound" phenomena: The symptoms that led to treatment with benzodiazepines recur in an enhanced form. These symptoms may be difficult to distinguish from the original symptoms for which the drug was prescribed.
Drug Abuse
Lorazepam has abuse potential. Patients with particular risk include those with a history of drug and/ or alcohol abuse.
Drug abuse is a known risk for benzodiazepines, and patients should be monitored accordingly when receiving lorazepam. Benzodiazepines may be subject to diversion. There have been reports of overdose related deaths when benzodiazepines are abused with other CNS depressants including opioids, other benzodiazepines, alcohol and/or illicit substances. These risks should be considered when prescribing or dispensing lorazepam. To reduce these risks the lowest effective dose should be used, and patients should be advised on the proper storage and disposal of unused drug to prevent diversion (e.g. through friends and relatives).
Duration
Treatment should be as short as possible. Generally, the duration of treatment varies from a few days to 4 weeks including the tapering off process.
It may be useful to inform the patient that treatment will be of limited duration and that it will be discontinued gradually. The patient should also be made aware of the possibility of "rebound" phenomena to minimise anxiety should they occur.
There are indications that, in the case of benzodiazepines with a short duration of action, withdrawal phenomena can become manifest within the dosage interval, especially when the dosage is high.
When benzodiazepines with a long duration of action are being used it is important to warn against changing to a benzodiazepine with a short duration of action, as withdrawal symptoms may develop.
Amnesia
Transient anterograde amnesia or memory impairment has been reported in association with the use of benzodiazepines. This effect may be advantageous when lorazepam is used as a premedicant. However, if lorazepam is used for insomnia due to anxiety, patients should ensure that they will be able to have a period of uninterrupted sleep which is sufficient to allow dissipation of drug effect (e.g., 7-8 hours).
Psychiatric and paradoxical reactions
Paradoxical reactions have been occasionally reported during benzodiazepine use (see section 4.8). Such reactions may be more likely to occur in children and the elderly. Should these occur, use of the drug should be discontinued.
Specific patient groups
Lorazepam is not intended for the primary treatment of psychotic illness or depressive disorders, and should not be used alone to treat depressed patients. The use of benzodiazepines may have a disinhibiting effect and may release suicidal tendencies in depressed patients. Therefore, large quantities of lorazepam should not be prescribed to these patients. The use of benzodiazepines in these patients should not be used without adequate antidepressant therapy.
Pre-existing depression may emerge during benzodiazepine use.
Caution should be used in the treatment of patients with acute narrow-angle glaucoma.
Patients with impaired renal function or mild to moderate hepatic insufficiency should be monitored frequently and have their dosage adjusted carefully according to patient response. Lower doses may be sufficient in these patients. The same precautions apply to elderly or debilitated patients and patients with chronic respiratory insufficiency.
As with all CNS-depressants, the use of benzodiazepines may precipitate encephalopathy in patients with severe hepatic insufficiency. Therefore, use in these patients is contraindicated.
Some patients taking benzodiazepines have developed a blood dyscrasia, and some have had elevations in liver enzymes. Periodic haematologic and liver-function assessments are recommended where repeated courses of treatment are considered clinically necessary.
Although hypotension has occurred only rarely, benzodiazepines should be administered with caution to patients in whom a drop in blood pressure might lead to cardiovascular or cerebrovascular complications. This is particularly important in elderly patients. Elderly patients should be warned of the risk of falls due to the myorelaxant effect of lorazepam.
Elderly patients:
Lorazepam should be used with caution in elderly due to the risk of sedation and/or musculoskeletal weakness that can increase the risk of falls, with serious consequences in this population. Elderly patients should be given a reduced dose (see section 4.2 Posology).
Excipient Warnings:
This medicinal product contains 20.21mg ethanol (alcohol) per ml. The amount in each ml of this medicinal product is equivalent to less than 1ml beer or 1ml wine. The small amount of alcohol in this medicinal product will not have any noticeable effects.
Not recommended: Concomitant intake with alcohol
The sedative effects may be enhanced when the product is used in combination with alcohol. This affects the ability to drive or use machines.
The benzodiazepines, including lorazepam produce additive central nervous system (CNS) depressant effects, including respiratory depression when co-administered with other medications which themselves produce CNS depression e.g., opioids, barbiturates, antipsychotics, sedatives/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anaesthetics (see section 4.4).
An enhancement of the euphoria induced by narcotic analgesics may occur with benzodiazepine use, leading to an increase in psychic dependence.
Compounds which inhibit certain hepatic enzymes (particularly cytochrome P450) may enhance the activity of benzodiazepines. To a lesser degree this also applies to benzodiazepines which are metabolised only by conjugation.
There have been reports of excessive stupor, significant reduction in respiratory rate and, in one patient, hypotension when lorazepam and loxapine have been given concomitantly.
There have been reports of marked sedation, excessive salivation, and ataxia when lorazepam and clozapine have been given concomitantly.
Concurrent administration of lorazepam with sodium valproate may result in increased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately 50% when co-administered with sodium valproate.
Concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately 50% when co-administered with probenecid.
Administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam.
Caffeine: Concurrent use may result in reduced sedative and anxiolytic effects of lorazepam.
Grapefruit juice: Inhibition of CYP3A4 may increase the plasma concentration of lorazepam (possible increased sedation and amnesia). This interaction may be of little significance in healthy individuals, but it is not clear if other factors such as old age or liver cirrhosis increase the risk of adverse events with concurrent use.
Pregnancy: Benzodiazepines should not be used during pregnancy, especially during the first and last trimesters. Benzodiazepines may cause foetal damage when administered to pregnant women. In particular, an increased risk of congenital malformations associated with the use of benzodiazepines during the first trimester of pregnancy has been suggested in several studies. In humans, umbilical cord blood samples indicate placental transfer of benzodiazepines and their glucuronide metabolites.
If the drug is prescribed to a woman of childbearing potential, she should be warned to contact her physician about stopping the drug if she intends to become, or suspects that she is, pregnant.
If, for compelling medical reasons, the product is administered during the late phase of pregnancy, or during labour at high doses, effects on the neonate can be expected due to the pharmacological action of the compound.
Infants of mothers who ingested benzodiazepines for several weeks or more preceding delivery have been reported to have withdrawal symptoms during the postnatal period.
Symptoms such as hypoactivity, hypotonia, hypothermia, respiratory depression, apnoea, feeding problems, and impaired metabolic response to cold stress have been reported in neonates born of mothers who have received benzodiazepines during the late phase of pregnancy or at delivery.
Breast-feeding
There is evidence that lorazepam is excreted, albeit in pharmacologically insignificant amounts, in human breast milk. Therefore, lorazepam should not be given to breastfeeding mothers unless the expected benefit to the mother outweighs the potential risk to the infant. Sedation and inability to suckle have occurred in neonates of lactating mothers taking benzodiazepines. Infants of lactating mothers should be observed for pharmacological effects (including sedation and irritability).
Sedation, amnesia, impaired concentration and impaired muscular function may adversely affect the ability to drive or to use machines. If insufficient sleep occurs, the likelihood of impaired alertness may be increased (see section 4.5). Patients should be warned not to operate dangerous machinery or motor vehicles if any of these effects occur.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
However, you would not be committing an offence (called 'statutory defence') if:
• The medicine has been prescribed to treat a medical or dental problem and
• You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
• It was not affecting your ability to drive safely.
Adverse reactions, when they occur, are usually observed at the beginning of therapy and generally decrease in severity or disappear with continued use or upon decreasing the dose.
Most frequently reported adverse reactions associated with benzodiazepines include daytime drowsiness, dizziness, muscle weakness, and ataxia.
Adverse reactions are listed by frequency:
Very common (≥1/10); Common (≥1/100 to < 1/10); Uncommon (≥1/1,000 to < 1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000), Not known (cannot be estimated from the available data).
System Organ Class
Adverse Drug Reactions
Frequency Category
Very Common
(≥1/10)
Common
(≥1/100 to <1/10)
Uncommon
(≥1/1000 to <1/100)
Rare
(≥1/10000 to <1/1000)
Very Rare
(<1/10,000)
Not Known
Blood and lymphatic system disorders
Thrombocytopenia, agranulocytosis, pancytopenia
Immune system disorders
Hypersensitivity including anaphylaxis/ anaphylactoid reactions
Endocrine disorders
Inappropriate antidiuretic hormone secretion,
Metabolism and nutrition disorders
hyponatraemia
Psychiatric disorders
Confusion, depression and unmasking of depression
Change in libido, decreased orgasm
Disinhibition, euphoria, suicidal ideation/attempt, paradoxical reactions, including anxiety, agitation, excitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, hallucinations, drug abuse, drug dependence (see section 4.4)
Nervous system disorders
Drowsiness, sedation
Dizziness, ataxia
Extrapyramidal symptoms, tremor, dysarthria/slurred speech, headache, convulsions/seizures, amnesia, coma, impaired attention/ concentration, balance disorder
Eye disorders
Visual disturbances (diplopia, blurred vision)
Ear and labyrinth disorders
Vertigo
Vascular disorders
Hypotension (see section 4.4)
Respiratory, thoracic and mediastinal disorders
Respiratory depression, βapnea, worsening of sleep apnea, worsening of obstructive pulmonary disease
Gastrointestinal disorders
Nausea
Constipation
Hepatobiliary disorders
Jaundice
Skin and subcutaneous tissue disorders
Angioedema, allergic skin reactions, alopecia
Musculoskeletal disorders
Muscle weakness
Reproductive system and breast disorders
Impotence
General disorders
Fatigue
Asthenia
Hypothermia, drug withdrawal syndrome
Investigations
Increase in bilirubin, increase in liver transaminases, increase in alkaline phosphatase
Injury, poisoning and procedural complications
Fall
± Benzodiazepine effects on the CNS are dose-dependent, with more severe CNS depression occurring with high doses.
β The extent of respiratory depression with benzodiazepines is dose‑ dependent, with more severe depression occurring with high doses.
Withdrawal symptoms syndrome Withdrawal syndrome has been reported upon discontinuation of lorazepam (see section 4.4). Withdrawal symptoms vary and may include rebound insomnia, muscle pain, anxiety, tremor, sweating, agitation, confusion, headache, palpitations, tachycardia, delirium, nightmares, hallucinations, panic attacks, muscle aches/cramps, gastrointestinal disturbances and irritability. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations. In very rare cases, seizures may occur.
Pre-existing depression may emerge during benzodiazepine use.
Transient anterograde amnesia or memory impairment may occur using therapeutic doses, the risk increasing at higher doses (see section 4.4).
Paradoxical reactions such as restlessness, agitation, irritability, aggressiveness, delusion, rage, nightmares, hallucinations, psychoses, and inappropriate behaviour have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly (see section 4.4).
Use (even at therapeutic doses) may lead to physical or psychological dependence and discontinuation of treatment may result in withdrawal reactions or rebound phenomena (see section 4.4).
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
In the management of overdose with any drug, it should be borne in mind that multiple agents may have been taken.
Overdose of benzodiazepines is usually manifested by degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion, and lethargy. In more serious cases, and especially when other CNS-depressant drugs or alcohol are ingested, symptoms may include dysarthria, ataxia, paradoxical reactions, CNS depression, hypotension, hypotonia, respiratory depression, coma, and very rarely, death. In post marketing experience, overdose with lorazepam has occurred predominantly in combination with alcohol and/or other drugs.
When there is a risk of aspiration, induction of emesis is not recommended. If ingestion was recent, induced vomiting and/or gastric lavage should be undertaken followed by general supportive care, monitoring of vital signs and close observation of the patient. If there is no advantage in emptying the stomach, activated charcoal may be effective in reducing absorption. Hypotension, though unlikely, may be controlled with noradrenaline. Lorazepam is poorly dialysable.
The benzodiazepine antagonist, flumazenil may be useful in hospitalised patients for the management of benzodiazepine overdose. Flumazenil product information should be consulted prior to use. The physician should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Lorazepam 1mg/ml Oral Solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.